[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neuromodulation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neuromodulation":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,41,69,104,128,151,175,198,226,254,277,293,318,345,369,396],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100641068","percutaneous-neurostimulation-in-knee-osteoarthritis-100641068",false,"NCT07637682","Percutaneous Neurostimulation in Knee Osteoarthritis","Percutaneous Peripheral Temporary Neurostimulation in Moderate to Severe Knee Osteoarthritis","Inclusion Criteria:\n\n1. adults between the ages of 30 and 70 years with a clinical diagnosis of moderate to severe knee OA who suffered knee pain.\n2. Patients who cannot afford intra-articular injections or radiofrequency ablation (RFA).\n3. patients who had failed 2 different oral pain medications and 6 weeks of physical therapy.\n\nExclusion Criteria:\n\n1. Patients with OA show improvement in pain after physiotherapy.\n2. patients evaluated by an orthopaedic surgeon and deemed to be surgical candidates due to knee pathologies other than OA.\n3. pregnant patients.\n4. patients on anticoagulation therapy, who were not permitted to stop anticoagulation.\n5. patients with previous trauma, neurological or endocrine diseases like diabetes mellitus, and knee tumors; and patients with inflammatory arthritis.\n6. people who had received an intra-articular knee injection within the last 6 months.\n7. Patients with tendon tears, bursitis, or calcified tendonitis as proven by imaging.","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"NA","Peripheral nerve stimulation (PNS) is a drug-free pain management procedure that uses electrical impulses to target specific nerves and block pain signals. PNS helps decrease perception of pain, providing real answers to patients dealing with chronic knee pain. The case study discussed in this presentation is of the use of PNS targeting the superior lateral genicular nerve and the saphenous nerve for a patient with moderate to severe knee pain from osteoarthritis",[26,27],"Osteoarthritis (OA) of the Knee","Neuromodulation","RECRUITING","2026-06-16",{"date":31,"type":32},"2026-06-18","ACTUAL",{"date":34,"type":32},"2026-06-02",{"date":36,"type":20},"2026-11",{"name":38,"class":39},"Tanta University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100561921","neurophysiological-investigation-of-the-approach-avoidance-axis-in-ocd-applications-to-neuromodulation-100561921","NCT06596447","Neurophysiological Investigation of the Approach-avoidance Axis in OCD: Applications to Neuromodulation","Inclusion Criteria:\n\n1. Principal diagnosis of OCD per DSM-5;\n2. Adult between ages 18 and 64;\n3. At least a five-year history of treatment-refractory OCD that causes substantial subjective distress and impairment in functioning;\n4. Minimum score of 28 on the Y-BOCS;\n5. Failed an adequate trial of at least three SSRIs;\n6. Failed an adequate trial of clomipramine;\n7. Failed augmentation of one or more of the aforementioned drugs with at least one anti-psychotic medication;\n8. Failed an adequate trial of CBT for OCD, defined as 25 hours of documented exposure and response prevention (ERP) by an expert therapist;\n9. Stable psychotropic medical regimen for the month preceding surgery;\n10. Principal diagnosis of OCD who are approved by our multi-disciplinary team to undergo DBS surgery within two months of enrollment;\n11. Ability to provide fully informed, written consent;\n12. Availability of a family member or significant other who is willing to accompany patients to study visits if necessary.\n\nExclusion Criteria:\n\n1. Lifetime diagnosis of psychotic disorder such as schizophrenia;\n2. Alcohol or substance abuse\u002Fdependence within 6 months, excluding nicotine;\n3. Concern for high risk of suicidal behavior or impulsivity;\n4. Patient is \\[regnant or plans to become pregnant in the next 24 months;\n5. Need for diathermy;\n6. Existence of any neurological or medical condition\u002Fdisorder that makes the individual, in the opinion of the study team, a poor candidate to participate in the intended study procedures\n7. Comorbid psychiatric disorder that, in the opinion of the study team, may interfere with the candidate's ability to participate in study activities;\n8. Primary diagnosis of a Hoarding Disorder.","70 Years",{"count":49,"type":20},10,"OBSERVATIONAL","We will recruit 10 patients with OCD meeting established criteria for surgical evaluation. Following informed consent and baseline evaluations, each will be implanted with permanent DBS SenSight leads and the Medtronic Percept RC IPG, which has on-device neural recording capability and rechargeability.\n\nWe will collect a broad array of neurobehavioral data across two environments with complementary advantages: the clinic and the home. The first 2 Aims test our mechanistic hypothesis by studying the pattern of VS neural activity in the controlled environment of the lab\u002Fclinic during two complementary paradigms: one based on a psychophysical behavioral task, the other based on ERP, a therapeutic behavioral intervention. The third aim tests this hypothesis in an ambulatory, naturalistic setting with chronic neural on-device recordings paired with time resolved behavioral measures. We will investigate a possible common neural basis underlying approach and avoidance across these 3 paradigms.\n\nSubjects will participate in research at 7 critical timepoints during routine clinic visits (Fig. 4): before implant, 1 day before DBS activation, immediately after DBS activation, 2 weeks, 3 months, 6 months, and 12 months after DBS initiation. At these timepoints, patients will complete clinical assessments, perform the Probabilistic Approach Avoidance Task (PAAT), and conduct exposure trials under the guidance of a psychologist. The clinic offers the most controlled environment and provides opportunities for collecting high temporal resolution behavior synchronized to local field potential (LFP) recordings. These data will allow us to identify the degree of overlap in the time-resolved neural activity driving individual decisions to approach potential rewards or avoid potential aversive stimuli (Aim 1), and resist performing compulsions in order to achieve relief after OCD symptoms are triggered (Aim 2).\n\nAt home, our goal is to investigate patient trajectories along the approach-avoidance axis as OCD symptoms improve (Aim 3). We will leverage passive, on device recordings that occur in the background of everyday life activities and synchronize these neural recordings with data collected via wearables, ecological assessments, and video diaries. Capturing neural and behavioral data in the home environment is essential for understanding the neural and behavioral changes that occur over longer timescales than individual clinical visits. The neurobehavioral biomarkers generated by this dataset will provide trackable readouts of clinical status that could inform therapeutic decision-making and enable data driven intervention.",[53,27],"Obsessive Compulsive Disorder (OCD)",[55,56,57,58],"Obsessive Compulsive Disorder","OCD","Deep Brain Stimulation","DBS","NOT_YET_RECRUITING",{"date":61,"type":32},"2026-06-17",{"date":63,"type":20},"2026-08-01",{"date":65,"type":20},"2030-07-31",{"name":67,"class":39},"Baylor College of Medicine",2,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":80,"briefSummary":81,"conditions":82,"keywords":86,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":40},"100597125","repetitive-transcranial-magnetic-stimulation-combined-with-bimanual-therapy-for-upper-limb-stroke-rehabilitation-100597125","NCT07054424","Repetitive Transcranial Magnetic Stimulation Combined With Bimanual Therapy for Upper Limb Stroke Rehabilitation","Development of Repetitive Transcranial Magnetic Stimulation (rTMS) Combined With Machine-assisted Bimanual Therapy (BT) in Upper Limb Rehabilitation","Inclusion Criteria:\n\n1. Age 40-80 years;\n2. First-onset stroke patients;\n3. Patients diagnosed with cerebral infarction or hemorrhage through CT or MRI;\n4. Signed informed consent form by the patient and their family;\n5. Stable physiological parameters;\n6. Stroke occurred within the last 12 months;\n7. Patients with unilateral hand function impairment caused by the stroke;\n8. Upper limb muscle tone (Modified Ashworth Scale, MAS) less than 3 points;\n9. Able to follow two-step commands.\n\nExclusion Criteria:\n\n1. A history of epilepsy or family history of epilepsy;\n2. Presence of suicidal tendencies;\n3. Currently using medications that lower the seizure threshold;\n4. Pregnant or planning to become pregnant;\n5. Co-existing neurological diseases (such as multiple sclerosis, other neurodegenerative diseases, meningitis, brain abscess, or meningioma);\n6. Subjects with uncontrollable migraines caused by elevated intracranial pressure;\n7. Subjects taking antidepressants who cannot discontinue the medication;\n8. Subjects with sleep disorders during rTMS treatment;\n9. Subjects with cerebellar stroke or brainstem stroke;\n10. Cerebral ischemic disorders resulting from traumatic brain injury;\n11. Transient ischemic attacks (TIAs);\n12. History of bleeding tendency and other conditions affecting upper limb function, such as myasthenia gravis, systemic immune neuropathy, severe epilepsy, endocrine system disorders, wearers of external or internal cardiac pacemakers, individuals with metallic implants or orthopedic devices;\n13. Co-existing severe heart, liver, kidney dysfunction, or other serious physical illnesses;\n14. Subjects with impaired consciousness who cannot cooperate with examinations or treatments, such as those with mental disorders, or those with intellectual or cognitive impairments, severe dementia;\n15. Presence of implanted electronic devices in the body;\n16. Co-existing severe liver, kidney, or hematological disorders;\n17. Special vulnerable populations;\n18. Skin disease (e.g., pressure ulcers, trauma, cellulitis, etc.).","40 Years","80 Years",{"count":79,"type":20},54,[23],"The goal of this clinical trial is to evaluate whether combining repetitive transcranial magnetic stimulation (rTMS) with machine-assisted bimanual therapy (BT) can improve upper limb function in stroke patients. The participants will be individuals aged 40-80 years who have experienced a first-time ischemic or hemorrhagic stroke. The main questions it aims to answer are:\n\n* Does the combined therapy enhance motor recovery compared to traditional rehabilitation methods?\n* Are changes in brain activity associated with improvements in upper limb function?\n\nParticipants will be randomly assigned to different groups and will:\n\n* Receive rTMS stimulation on specific areas of the brain to modulate neural activity,\n* Perform machine-assisted bimanual exercises to promote motor skills, and\n* Undergo assessments before, immediately after, and during follow-up periods to measure functional improvements.",[83,84,85,27],"Post-stroke Upper Limb Hemiparesis","Repetitive Transcranial Magnetic Stimulation (rTMS)","Bimanual Therapy",[87,88,89,90,91,92,93,94],"Stroke","neurorehabilitation","rTMS","bimanual therapy","neuromodulation","upper limb function","theta burst stimulation","brain plasticity","2026-06-10",{"date":97,"type":32},"2026-06-11",{"date":99,"type":32},"2025-06-05",{"date":101,"type":20},"2027-07-31",{"name":103,"class":39},"Chang Gung Memorial Hospital",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":111,"sex":16,"minAge":17,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":21,"phases":115,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":40},"100535411","study-of-the-dynamics-of-verbal-and-non-verbal-interaction-in-healthy-subjects-through-the-recording-of-body-movements-and-non-invasive-neurophysiological-techniques-100535411","NCT06251479","Study of the Dynamics of Verbal and Non-verbal Interaction in Healthy Subjects, Through the Recording of Body Movements and Non-invasive Neurophysiological Techniques","OMNIBUS2023","Inclusion Criteria:\n\n* Age range between 18 and 55 years\n* written informed consent\n* healthy subjects\n\nExclusion Criteria:\n\n* epilepsy or at risk of epileptic seizures,\n* cardiac pacemaker wearers,\n* presence of an implanted infusion pump,\n* metal plaques in the skull or metal objects in the eye and skull taking neuroleptic drugs or tricyclic antidepressants,\n* migraine or at risk of developing this disease.",true,"55 Years",{"count":114,"type":20},200,[23],"Based on study literature, the investigators can say that our study aims to give an explanation not only from a behavioral point of view but also with respect to what are the neuronal mechanisms underlying our ability to perceive and analyze our own and others' actions. This is essential to fully understand the complexity of our social behaviors. The knowledge of these mechanisms has a high value and relevant implications for many research fields both within and outside the neurosciences. The project aims to study the neurobehavioral correlates of verbal and non-verbal communication. Through the use of non-invasive behavioral and neurophysiological techniques, the study intends to highlight the neurobehavioral markers that allow to quantify the temporal evolution of communication dynamics in healthy subjects.",[118,27],"Neuroscience","2026-03-26",{"date":121,"type":32},"2026-03-31",{"date":123,"type":32},"2023-08-16",{"date":125,"type":20},"2026-08-16",{"name":127,"class":39},"IRCCS Centro Neurolesi Bonino Pulejo",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":134,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":21,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":40},"100532454","harnessing-neuroplasticity-of-postural-sensorimotor-networks-using-non-invasive-spinal-neuromodulation-to-maximize-functional-recovery-after-spinal-cord-injury-100532454","NCT06213012","Harnessing Neuroplasticity of Postural Sensorimotor Networks Using Non-Invasive Spinal Neuromodulation to Maximize Functional Recovery After Spinal Cord Injury","Inclusion criteria\n\n1. All participants must be able to provide a provision of a signed and dated informed consent form.\n2. Stated willingness to comply with all study procedures and availability for the duration of the study.\n3. Male or female, aged 22-75 years old.\n4. Documentation from the participant's primary treating physician confirming a stable medical condition.\n5. Inability to maintain standing independently without external support due to SCI AIS A-C.\n6. Ability to tolerate at least 15 minutes in an upright (supported) position.\n7. Able to self-transfer from the wheelchair and demonstrate active range of motion of bilateral upper extremities in gravity dependent plane.\n8. Able to passively range bilateral lower extremities within normal mobility parameters including:\n\n   1. greater than 90 degrees of hip flexion and 165 degrees of hip extension;\n   2. greater than 90 degrees of knee flexion and reach neutral knee extension of 180 degrees;\n   3. neutral ankle position reaching a minimum of 90 degrees of dorsiflexion.\n9. Participants should be on a stable intrathecal baclofen or oral anti-spasticity regimen\u002Fdose for the period of the study unless advised otherwise by their physician.\n10. 1 to 30 years post spinal cord injury.\n11. Non-progressive spinal cord injury.\n12. Neurological level of injury below C4 and above T12 (excluding conus injury and\u002For indications of lower motor neuron injury).\n13. Eligible for fMRI per safety questionnaire.\n14. Women of childbearing potential must agree to the use of an effective means of avoiding pregnancy for the duration of the study.\n15. Able to commit to the full study.\n\nExclusion Criteria:\n\n1. Ability to maintain standing independently without external support.\n2. Currently involved in another rehabilitation training of the lower extremities.\n3. Active pressure sores, unhealed bone fractures, peripheral neuropathies, or painful musculoskeletal dysfunction (including but not limited to contractures in the upper and lower extremities).\n4. Any ongoing medical condition which would preclude participant from regular physical activity (including but not limited to: cardiopulmonary disease, uncontrollable autonomic dysreflexia or orthostatic hypotension, active urinary tract infections, pregnant or nursing).\n5. Intrathecal baclofen pump therapy for spasticity not compatible with 3T MRI.\n6. Must not have received Botox injections to primary lower extremity and trunk musculature within the past 3 months, resulting in absence of muscle tone and precluding response to electrical stimulation therapy.\n7. Current or history of neuromuscular conditions (including but not limited to: unhealed ligament of muscular tears in the upper or lower extremities, pain in weight bearing positions for upper and lower extremities).\n8. Clinically significant depression, psychiatric disorders, or ongoing drug abuse, including heavy alcohol use.\n9. Any reason the PI or treating physician may deem as harmful to the participant to enroll or continue in the study.\n10. Body Mass Index (BMI) over 30.\n11. Pregnancy.\n12. Use a ventilator or diaphragmatic pacer.\n13. Participants with the following conditions will be excluded from TMS, but may take part in the overall study:\n\n    * Personal or first-degree family history of seizures or epilepsy.\n    * Metal in the head, except mouth implants.\n    * History of suicide attempts.\n    * History of intracranial lesions, increased intracranial pressure, or stroke.\n    * Current use of tricyclic anti-depressants, selective serotonin reuptake inhibitors (SSRIs), serotonin nor-epinephrine reuptake inhibitors (SNRIs), buproprion (Wellbutrin), or tramadol.","22 Years","75 Years",{"count":137,"type":20},60,[23],"It has been demonstrated that the human lumbosacral spinal cord can be neuromodulated with epidural (ESS) and transcutaneous (TSS) spinal cord stimulation to enable recovery of standing and volitional control of the lower limbs after complete motor paralysis due to spinal cord injury (SCI). The work proposed herein will examine and identify distinct electrophysiological mechanisms underlying transcutaneous spinal stimulation (TSS) and epidural spinal stimulation (ESS) to define how these approaches determine the ability to maintain self-assisted standing after SCI.",[141,27],"Spinal Cord Injuries","2026-03-25",{"date":144,"type":32},"2026-03-30",{"date":146,"type":32},"2023-12-06",{"date":148,"type":20},"2027-08-31",{"name":150,"class":39},"The Methodist Hospital Research Institute",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":21,"phases":159,"briefSummary":160,"conditions":161,"keywords":163,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":40},"100563031","ultrasound-neuromodulation-in-essential-tremor-100563031","NCT06610877","Ultrasound Neuromodulation in Essential Tremor","UNMET","Inclusion Criteria:\n\n* Patients with medically refractory tremor scheduled to undergo MR-guided high-intensity focused ultrasound (HIFU) thalamotomy to treat their tremor at UCSF.\n\nExclusion Criteria:\n\n* Due to the logistical complexity of performing MRI in patients with MR-conditional pacemakers (need for device and patient monitoring), patients with pacemakers will be excluded from enrollment. All other patients undergoing HIFU thalamotomy for tremor will be eligible for enrollment.",{"count":137,"type":20},[23],"This study is being done to test whether low-intensity focused ultrasound (LIFU) (low energy sound waves) cause temporary changes in brain activity and behavior when directed at particular parts of the brain. By targeting LIFU to the parts of the brain thought to be responsible for essential tremor (ET), and measuring any associated improvement in tremor, the investigators hope to show that LIFU can be a useful tool for studying the brain circuits responsible for tremor and other brain disorders.",[162,27],"Essential Tremor",[162,27,164,165],"Focused Ultrasound","brain functional connectivity","2026-03-04",{"date":168,"type":32},"2026-03-06",{"date":170,"type":32},"2024-10-01",{"date":172,"type":20},"2027-03",{"name":174,"class":39},"University of California, San Francisco",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":21,"phases":183,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":40},"100622532","the-role-of-transcutaneous-vagus-nerve-stimulation-in-treatment-of-acute-brain-injury-100622532","NCT07384845","The Role of Transcutaneous Vagus Nerve Stimulation in Treatment of Acute Brain Injury","The Role of Transcutaneous Vagus Nerve Stimulation in Neuroprotection and the Reduction of the Systemic Inflammatory Response in Acute Brain Injury","IInclusion Criteria:\n\nPatients over 18 years of age with a diagnosis of traumatic brain injury or acute subarachnoid hemorrhage due to rupture of an intracranial aneurysm, confirmed by brain CT or MRI.\n\nExclusion Criteria:\n\nPatients under 18 years of age; patients with autoimmune diseases or malignant diseases; pregnant women; and patients for whom informed consent to participate in the study is not obtained.",{"count":137,"type":20},[23],"Acute brain injury is a major global health problem associated with high mortality and morbidity, limited therapeutic options, prolonged hospital stays, and long-term disability that significantly impairs quality of life and increases healthcare costs. Noninvasive transcutaneous VNS developed as a safer approach for treating cerebral edema, epileptic seizures, and blood-brain barrier disruption, for facilitating the recovery of motoric and cognitive functions, and for immunomodulation.\n\nTranscutaneous VNS improves cerebral perfusion pressure and tissue oxygenation, supports reperfusion of the penumbral zone, and reduces neuronal hyperexcitability, thereby suppressing seizures.It may exert anti-inflammatory effects by reducing microglial cytokine and chemokine production. Additionally, vagal stimulation promotes acetylcholine-mediated suppression of pro-inflammatory cytokines, including TNF, IL-1β, IL-6, and IL-18.\n\nAnother anti-inflammatory mechanism involves ghrelin, a peptide hormone whose serum levels increase under vagal stimulation. Elevated ghrelin reduces TNF-α and other pro-inflammatory cytokines and may limit intracerebral hemorrhage by inhibiting the NLRP3 inflammasome and activating the Nrf2\u002FARE signaling pathway. Biomarkers such as S100 protein and neuron-specific enolase (NSE) are valuable indicators of brain tissue damage and clinical outcomes; tVNS may reduce their levels and support non-invasive monitoring of disease progression.\n\nThe technique is considered safe in patients .\n\nTo date, tVNS has not been evaluated in clinical trials in Croatia, nor reported in case studies or cohort analyses. Study outcomes will be correlated with patients' clinical status, duration and course of hospitalization, complication rates, and overall treatment outcomes.",[186,187,27,188],"Acute Brain Injury","Transcutaneous Vagus Nerve Stimulation","Immunomodulation","2026-01-26",{"date":191,"type":32},"2026-02-03",{"date":193,"type":20},"2026-02",{"date":195,"type":20},"2028-02",{"name":197,"class":39},"Clinical Hospital Centre Zagreb",{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":16,"minAge":205,"maxAge":206,"enrollmentInfo":207,"targetDuration":4,"studyType":21,"phases":208,"briefSummary":209,"conditions":210,"keywords":212,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":40},"100616415","characterising-the-network-specific-effects-of-piriform-cortex-stimulation-via-seeg-100616415","NCT07305311","Characterising the Network-Specific Effects of Piriform Cortex Stimulation Via SEEG","Characterising the Network-Specific Effects of Piriform Cortex Stimulation Via SEEG With Multimodal Data Integration","Inclusion Criteria:\n\n* The patients were diagnosed with drug-resistant epilepsy.\n* The patients underwent stereoelectroencephalography (SEEG) implantation for pre-surgical evaluation of epilepsy, with at least one electrode target reaching the piriform cortex\n* Participants\u002Fparents\u002Flegal guardian provide informed consent for inclusion\n\nExclusion Criteria:\n\n* Subjects that experience surgical complications during the implant procedure will be excluded from the study","14 Years","65 Years",{"count":49,"type":20},[23],"The prospective study aims to characterize the network-specific modulatory effects of piriform cortex stimulation in patients undergoing stereotactic EEG for drug-resistant epilepsy. Using multimodal data, it seeks to link stimulation-evoked electrophysiological responses across brain networks with clinical outcomes, to inform targeted neuromodulation therapies.",[211,27],"Refractory Epilepsy",[213,214,215,216],"SEEG","Piriform cortex","Electrical stimulation","Electrophysiology","2025-12-12",{"date":219,"type":32},"2025-12-26",{"date":221,"type":20},"2025-12-08",{"date":223,"type":20},"2027-11-08",{"name":225,"class":39},"Xuanwu Hospital, Beijing",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":111,"sex":16,"minAge":17,"maxAge":233,"enrollmentInfo":234,"targetDuration":4,"studyType":21,"phases":235,"briefSummary":236,"conditions":237,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":4},"100612630","effects-of-transcutaneous-auricular-vagus-nerve-stimulation-on-cognitive-performance-and-sex-differences-100612630","NCT07256080","Effects of Transcutaneous Auricular Vagus Nerve Stimulation on Cognitive Performance and Sex Differences","A Sham-Controlled Cross-Over Study Examining the Effects of Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) on Cognitive Performance and Gender Differences in Healthy Adults","Inclusion Criteria:\n\n* Healthy young adults aged 18-30 years\n* Ability to provide informed consent\n* Right-handed participants (to reduce variability in cognitive performance)\n* Normal or corrected-to-normal vision and hearing\n* Female participants tested during the follicular phase of the menstrual cycle (days 5-10) to minimize hormonal effects on cognition and vagal tone\n\nExclusion Criteria:\n\n* History of neurological or psychiatric disorders\n* Cardiovascular disease\n* Use of psychoactive medications\n* Substance dependence, including alcohol, illicit drugs, or nicotine\n* Pregnancy or breastfeeding\n* Skin conditions or ear anomalies that interfere with electrode placement\n* Metal implants in the head or neck region\n* History of epilepsy or migraine","30 Years",{"count":137,"type":20},[23],"This study investigates the effects of transcutaneous auricular vagus nerve stimulation (taVNS) on cognitive performance in healthy adults. The study uses a sham-controlled, cross-over design in which each participant receives both active taVNS and sham stimulation in separate sessions. Each participant completes both conditions (active and sham) in a randomized order using a crossover design. Cognitive performance will be assessed before and after each session using standardized tests. The study also explores whether males and females respond differently to taVNS, in order to identify potential sex-related differences in cognitive outcomes.",[238,239,240,241,242,243,27,244],"Cognitive Assessment","Cognition","taVNS","Vagus Nerve Stimulation","Executive Functions","Healthy Participants","Sex Differences","2025-11-27",{"date":247,"type":32},"2025-12-01",{"date":249,"type":20},"2025-12",{"date":251,"type":20},"2026-05",{"name":253,"class":39},"Bahçeşehir University",{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":260,"enrollmentInfo":261,"targetDuration":4,"studyType":21,"phases":263,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":4},"100605659","analysis-of-neuromodulation-as-a-complementary-treatment-to-evidence-based-clinical-intervention-in-subjects-with-musculoskeletal-pathology-of-the-upper-limb-a-double-blind-randomized-clinical-trial-100605659","NCT07165392","Analysis of Neuromodulation as a Complementary Treatment to Evidence-based Clinical Intervention in Subjects With Musculoskeletal Pathology of the Upper Limb: a Double-blind Randomized Clinical Trial","Inclusion Criteria:\n\n* Participants in the study will be men and women of working age, diagnosed with musculoskeletal disorders of the upper limb, and who have not yet received physical therapy.\n\nExclusion Criteria:\n\n* Have undergone surgery.\n* Those who refuse to participate in this study.\n* Patients who present muscular atrophy in the upper limb due to a pathology of the latter.\n* Medical conditions that are contraindications for neuromodulation therapy","60 Years",{"count":262,"type":20},120,[23],"This project aims to analyze the use of neuromodulation within a treatment protocol for musculoskeletal conditions of the upper limb, as well as to determine the difference between two and three sessions per week. Study participants will be divided into four intervention groups: the first will receive two sessions per week for a period of six months, while the second will receive three sessions per week for the same period. The treatment protocol will consist of therapeutic physical exercise focused on the muscles and joints of the lower limb, stretching of the involved muscles, and neuromodulation of the brachial plexus nerve root, which innervates the affected structures. The third and fourth intervention groups will receive the same treatment as mentioned above, but without neuromodulation. The third group will receive three sessions per week, while the second group will receive two sessions per week. Two different types of measurement variables will be used: objective variables will be used to measure range of motion and muscle strength. Subjective variables will also be used through validated questionnaires, covering physical activity, health-related quality of life, upper limb function, and a visual analog scale for pain perception.",[27,266,267],"Upper Limb","Musculoskeletal Disorders","2025-09-02",{"date":270,"type":32},"2025-09-10",{"date":272,"type":20},"2025-10-01",{"date":274,"type":20},"2027-03-31",{"name":276,"class":39},"University of Malaga",{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":260,"enrollmentInfo":283,"targetDuration":4,"studyType":21,"phases":285,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":289,"startDateStruct":290,"completionDateStruct":291,"leadSponsor":292,"locationsCount":4},"100605658","analysis-of-neuromodulation-as-a-complementary-treatment-to-evidence-based-clinical-intervention-in-subjects-with-musculoskeletal-pathology-of-the-lower-limb-a-double-blind-randomized-clinical-trial-100605658","NCT07165379","Analysis of Neuromodulation as a Complementary Treatment to Evidence-based Clinical Intervention in Subjects With Musculoskeletal Pathology of the Lower Limb: a Double-blind Randomized Clinical Trial","Inclusion Criteria:\n\n* Participants in the study will be men and women of working age, diagnosed with musculoskeletal disorders of the lower limb, and who have not yet received physical therapy.\n\nExclusion Criteria:\n\n* Have undergone surgery.\n* Those who refuse to participate in this study.\n* Patients who present muscular atrophy in the lower limb due to a pathology of the latter.\n* Medical conditions that are contraindications for neuromodulation therapy",{"count":284,"type":20},64,[23],"This project aims to analyze the use of neuromodulation within a treatment protocol for musculoskeletal conditions of the lower limb, as well as to determine the difference between two and three sessions per week. Study participants will be divided into four intervention groups: the first will receive two sessions per week for a period of six months, while the second will receive three sessions per week for the same period. The treatment protocol will consist of therapeutic physical exercise focused on the muscles and joints of the lower limb, stretching of the involved muscles, and neuromodulation of the nerve root of the lumbosacral plexus, which innervates the affected structures. The third and fourth intervention groups will receive the same treatment as mentioned above, but without neuromodulation. The third group will receive three sessions per week, while the second group will receive two sessions per week. Two different types of measurement variables will be used: objective variables will be used to measure range of motion and muscle strength. Subjective variables will also be used through validated questionnaires, covering physical activity, health-related quality of life, lower limb function, and a visual analog scale for pain perception.",[27,288,267],"Lower Limb",{"date":270,"type":32},{"date":272,"type":20},{"date":274,"type":20},{"name":276,"class":39},{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":111,"sex":16,"minAge":76,"maxAge":77,"enrollmentInfo":300,"targetDuration":4,"studyType":21,"phases":302,"briefSummary":304,"conditions":305,"keywords":307,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":314,"leadSponsor":316,"locationsCount":40},"100605175","early-phase-1-tdcs-for-cancer-related-fatigue-and-weakness-100605175","NCT07159100","tDCS for Cancer-Related Fatigue and Weakness","Neuromodulation as a Therapeutic Intervention to Improve Cancer Related Fatigue and Weakness","General Inclusion - All participants\n\n1. Aged 40-80\n2. Right Handed, as determined by the Edinburgh Inventory 21\n3. Proficient in English\n4. Must be available for the familiarization, and testing sessions\n\nGeneral Inclusion - Cancer Patients only\n\n1. Cancer (\\>6 months post therapy)\n2. Suffers from a subjective feeling of cancer related fatigue and weakness as assessed by the following question: \"Do you suffer from symptoms of fatigue and weakness related to your cancer or cancer treatment?\"\n3. Have had cancer diagnosis and treatment in the past\n4. Must have a stable physical\u002Fhealth condition for the past 3 months with no expected changes for the duration of the study\n\nGeneral Exclusion - All participants\n\n1. Neurological, psychiatric, musculoskeletal or other types of disorder not caused by cancer and\u002For cancer treatment, which may affect participants sensorimotor function and cognitive abilities\n2. No consciousness to understand and sign informed consent voluntarily\n3. History of alcohol, and illicit drug use\n4. History of smoking within the last 5 years.\n\nGeneral Exclusion - Cancer Patients 1. Radiation, surgery, chemo, or other cancer treatment therapies in the past 6 months prior to enrollment. Hormonal maintenance treatment is allowed.\n\nGeneral Exclusion - Healthy Participants\n\n1\\. History of cancer or cancer treatment\n\nExclusion criteria related to tDCS and TMS safety - All participants\n\n1. History of epilepsy or unprovoked seizures\n2. Family history of epilepsy (father, mother, children, siblings with diagnosis of epilepsy)\n3. Active migraine headaches\n4. Past or current history of treated tinnitus or severe hearing problems\n5. Implanted medical devices (pacemakers, defibrillators, medical pump, implanted brain stimulator, aneurysm clip, carotid or cerebral stents, central venous catheter, non-removable hearing aids)\n6. Damage to the skin on the scalp\n7. History of mental illness (schizophrenia, anxiety, major depression, manic disorders)\n8. Tattoo with metal based ink in the head or neck\n9. Currently taking or withdrawing from any central nervous system active medication (stimulants, anticonvulsants, antidepressants, psychotropic medications).\n10. Pregnant as determined by a Pregnancy test for non-menopausal (no menstruation for at least 1 year) women younger than 55 years (for TMS and fMRI only).\n\nExclusion criteria related to MRI safety - All participants\n\nWe will be using the Kessler Foundation RONIC MRI center screening form to screen participants for the MRI scan. Exclusion criteria includes:\n\n1. Suffer from claustrophobia (fear of confined spaces)\n2. Prior injury to the eye involving a metallic object or fragment (e.g., metallic slivers, shavings, foreign body, etc.)?\n3. Presence or prior injury by a metallic object, or foreign body or metallic fragment (e.g., BB, bullet, shrapnel, etc.)\n4. Currently or former metal worker (welder, machinist, etc.)\n5. Implanted electrical devices (e.g. pacemakers, defibrillators or ICD)\n6. Implanted stimulators or internal electrodes or wires (neurostimulator, brain stimulator, spinal cord, bone growth\u002Fbone fusion)\n7. Aneurysm clips (metal clips on the wall of a large artery), metallic stent, shunt (spinal)\n8. Metallic prostheses or implants (including metal pins and rods, plate, screw, surgical staples, clips or metallic sutures, joint replacement (hip, knee), cochlear or other otologic implant, eye, penile, heart valves, eyelid spring or wires, prosthetic limbs)\n9. Dental implants, dentures or partial plates (regular filling, amalgam and crown are OK)\n10. Insulin, medication or other infusion pumps\n11. Radiation seeds or implants\n12. Transdermal medication patch (Nitroglycerine, Nicotine)\n13. IUD, diaphragm or pessary\n14. Tissue expander (e.g. breast)\n15. Body tattoos or permanent makeup (eyeliner, lip) if deemed unsafe in the MRI\n16. Body piercing",{"count":301,"type":20},75,[303],"EARLY_PHASE1","This pilot study investigates the effectiveness of non-invasive brain stimulation (tDCS) in alleviating cancer-related fatigue (CRF) and muscle weakness. Using a randomized, double-blind crossover design, participants perform fatiguing muscle tasks with and without tDCS, and outcomes include task endurance, maximal voluntary contraction force, and neuromuscular markers. Neural mechanisms will be assessed via EEG, TMS, and MRI.",[306,27],"Cancer-related Fatigue",[308,309,91],"tDCS","Cancer-related fatigue","2025-08-28",{"date":312,"type":32},"2025-09-08",{"date":270,"type":20},{"date":315,"type":20},"2027-12-31",{"name":317,"class":39},"Kessler Foundation",{"id":319,"slug":320,"hasResults":11,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":324,"eligibilityCriteria":325,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":326,"targetDuration":4,"studyType":21,"phases":328,"briefSummary":329,"conditions":330,"keywords":332,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":40},"100592680","study-to-compare-the-clinical-effectiveness-and-cost-utility-of-an-all-in-one-procedure-with-an-at-home-screening-trial-100592680","NCT06996574","Study to Compare the Clinical Effectiveness and Cost Utility of an All-in-one Procedure With an At-home Screening Trial","A Pragmatic Randomised Prospective Multi-centre Non-inferiority Trial in Chronic Pain Patients With Closed-loop Spinal Cord Stimulation (CL-SCS) to Compare the Clinical Effectiveness and Cost Utility of an All-in-one Procedure With an At-home Screening Trial","All-in-one","Inclusion Criteria:\n\n1. Diagnosed with chronic, neuropathic pain with an approved aetiology in the Netherlands PSPS (persistent spinal pain syndrome) PDN (painful diabetic neuropathy) CRPS (complex regional pain syndrome) SFN (small fibre neuropathy)\n2. Suitable candidate according to the inclusion criteria of the Dutch \"Standpoint on Neuromodulation in Chronic Pain\" Adult patients ≥18 years Chronic pain ≥6 months Pain intensity of ≥50mm or ≥5 on VAS- or NRS-score respectively\n3. Routinely selected for CL-SCS\n4. Be willing to complete additional trial related questionnaires\n5. Be willing and capable of giving informed consent.\n\nExclusion Criteria:\n\n1. General exclusion criteria according to the Dutch \"Standpoint on Neuromodulation in Chronic Pain\":\n\n   Drug abuse Pregnancy Coagulation disorder \u002F Use of anticoagulation therapy which cannot be stopped temporarily Active infection Life expectation ≤12 months Intake questionnaires \"PROMS neuromodulatie\" not completed by the patient\n2. Have an existing drug pump and\u002For SCS system or another active implantable device such as a pacemaker, deep brain stimulator (DBS), or sacral nerve stimulator (SNS)\n3. Current or previous treatment with an implanted pain reduction device\n4. Participation in another clinical trial that may confound the results of this trial",{"count":327,"type":20},180,[23],"In 2019, the Dutch Healthcare Institute published a consensus report outlining when spinal cord stimulation (SCS) for chronic pain qualifies for reimbursement under Dutch health insurance. It mandates that adult patients with significant pain (VAS ≥50mm or NRS ≥5) undergo an at-home screening trial, which must show at least 50% pain reduction to proceed with permanent implantation. Screening trials give patients early access to the therapy, but they are expensive, often redundant, and pose risks such as infection. A recent UK study (TRIAL-STIM) found no significant difference in outcomes between patients who had screening trials and those who received an all-in-one SCS procedure, but the trial strategy incurred greater costs. Given these findings, and the fact that all-in-one procedures are already used in certain Dutch cases, it is reasonable to evaluate this approach more broadly. Therefore, a pragmatic, multi-centre, randomized non-inferiority trial will compare the effectiveness of the all-in-one procedure, no trial group (NTG) to the standard two-step approach, trial group (TG) in Dutch patients with chronic neuropathic pain.",[27,331],"Chronic Pain Patients",[91,333,334,335],"chronic pain","SCS procedure","standard of care","2025-07-06",{"date":338,"type":32},"2025-07-10",{"date":340,"type":32},"2025-06-06",{"date":342,"type":20},"2028-04-01",{"name":344,"class":39},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":349,"acronym":350,"eligibilityCriteria":351,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":352,"targetDuration":4,"studyType":21,"phases":354,"briefSummary":355,"conditions":356,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":40},"100555679","improving-pelvic-rehabilitation-using-epidural-stimulation-after-spinal-cord-injury-100555679","NCT06515223","Improving Pelvic Rehabilitation Using Epidural Stimulation After Spinal Cord Injury","ImPRESS","Inclusion Criteria:\n\n* Spinal Cord Injury (supra-sacral)\n* AIS A-D\n* \\>18 years;\n* SCI sustained \\>12 months ago;\n* Neurogenic detrusor overactivity (NDO) confirmed on urodynamics;\n* Responsive to dorsal genital nerve stimulation\n* Willing and able to provide informed consent\n* Stable medical, physical and psychological condition as considered by the investigators\n* Able to understand and interact with the study team in English\n* Sufficient upper limb function to operate the device\n* Suitably optimised bladder and bowel routine\n\nExclusion Criteria:\n\n* Transected cord or SCI related to a neurodegenerative disease\n* Any device or metal work in situ that would exclude the patient from having eSCS implanted\n* Intra-detrusor botulinum toxin injections within the last 6 months\n* Previous surgical intervention on bladder sphincters\n* Any diseases and conditions that would exclude the patient from eSCS and\u002For surgery, for example, degenerative spinal pathology, syrinx and\u002For tumor.\n* Recurrent urinary tract infection refractory to antibiotics\n* Women who are pregnant or intending to become pregnant (pregnancy test obligatory for woman of childbearing potential) or breast feeding, or lack of safe contraception for women of childbearing capacity.\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders or dementia of the participant\n* Participation in another study with investigational drug within the 30 days preceding and during the present study\n* Enrolment of the investigator, his\u002Fher family members, employees, and other dependent persons.",{"count":353,"type":20},20,[23],"The investigators will recruit up to 20 volunteers with chronic, supra-sacral SCI. Following screening, eligible participants will enter 'Phase I', they will complete baseline outcome measures and then have the epidural spinal cord stimulator (eSCS) implanted with either percutaneous or paddle electrodes. Preoperative and intraoperative testing will determine exact location of electrodes.\n\nMapping and optimisation of stimulation parameters will be performed simultaneously with urodynamic investigations of bladder function, and anorectal physiology investigations of bowel function. The acute effects of eSCS to suppress bladder overactivity, facilitate voiding, prevent unwanted reflex sphincter activity, and pelvic floor function will guide development of eSCS programmes for use at home.\n\nIn 'Phase II', participants will use eSCS at home for 12-weeks. Participants will also be taught how to perform bladder and pelvic floor muscle training (PFMT) in combination with eSCS.\n\nOutcome measures assessing bladder, bowel, sexual function, quality of life, motor function and spasticity will be captured prior to and following the 12-week intervention, and at 3 and 6 month follow up.",[141,27,357,358,359],"Neurogenic Bladder","Neurogenic Bowel","Neurogenic Detrusor Overactivity","2025-03-13",{"date":362,"type":32},"2025-03-14",{"date":364,"type":32},"2024-10-14",{"date":366,"type":20},"2027-11-01",{"name":368,"class":39},"University College, London",{"id":370,"slug":371,"hasResults":11,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":111,"sex":16,"minAge":17,"maxAge":376,"enrollmentInfo":377,"targetDuration":4,"studyType":21,"phases":379,"briefSummary":380,"conditions":381,"keywords":382,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":40},"100551773","optimization-of-itbs-for-depression-100551773","NCT06464445","Optimization of ITBS for Depression","Defining Parameters to Optimize Neurostimulation for the Treatment of Pediatric Depression","Inclusion Criteria:\n\n* Be between 18 and 35 years old\n* Be of right manual dominance\n* In good health\n\nExclusion Criteria:\n\n* Have an implant or pacemaker,\n* Having tinnitus,\n* Have a history of fainting,\n* Have already had an epileptic seizure or have a family history of epilepsy,\n* Have a known neurological disease,\n* Be under psychotropic medication,\n* Have suffered from substance abuse or dependence in the last 6 months,\n* Have a neurostimulator,\n* Have a splinter or metallic implant in the head or the rest of the body,\n* Have a cochlear implant,\n* Have an automated injection system implanted (insulin pump),\n* Have a transdermal patch,\n* Have tattoos in the area to be studied,\n* Be pregnant or breastfeeding,","35 Years",{"count":378,"type":20},30,[23],"Repetitive TMS (rTMS) is a well-established method for modulating brain activity. Through successive stimulations in the form of magnetic fields, it is possible to modify the sensitivity of neurons in the brain, also known as cortical excitability. Cortical excitability is important for the induction of brain plasticity, the ability of the brain to reorganize itself and form new connections in response to stimuli. A particular class of rTMS, intermittent theta burst TMS (iTBS), is commonly used to modulate cortical excitability and induce plasticity for therapeutic purposes, notably for treatment-resistant depression.\n\nDifferent iTBS stimulation parameters can be used to induce plasticity. This study will focus on two parameters, namely, the form and duration of the electromagnetic stimulation. The shape of the electromagnetic pulse refers to how the electromagnetic wave is configured over time, while the duration is simply the period during which this electromagnetic pulse remains active. These parameters are expected to influence the effectiveness of iTBS in modulating cortical activity but remain little studied.\n\nThe main aim of this study will be to compare the effectiveness of different stimulation parameters in the induction of plasticity, which will then make it possible to improve the rTMS protocols used for treatment-resistant depression.",[27],[383,384,385,386],"TMS","repetitive TMS","intermittent Theta Burst Stimulation","Plasticity","2025-02-05",{"date":389,"type":32},"2025-02-10",{"date":391,"type":32},"2024-08-01",{"date":393,"type":20},"2026-07-01",{"name":395,"class":39},"Université de Sherbrooke",{"id":397,"slug":398,"hasResults":11,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":11,"sex":16,"minAge":205,"maxAge":403,"enrollmentInfo":404,"targetDuration":4,"studyType":21,"phases":406,"briefSummary":407,"conditions":408,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":40},"100516136","safety-feasibility-and-efficacy-of-tscs-on-stabilizing-blood-pressure-for-acute-inpatients-with-sci-100516136","NCT06000592","Safety, Feasibility, and Efficacy of TSCS on Stabilizing Blood Pressure for Acute Inpatients With SCI","Safety, Feasibility, and Efficacy of Transcutaneous Spinal Cord Stimulation on Stabilizing Blood Pressure for Acute Inpatients With Spinal Cord Injury","Inclusion Criteria:\n\n* Newly injured patients with traumatic SCI\n* Admitted to Acute Inpatient Rehabilitation at Mount Sinai\n* Within one year of SCI\n* Seated hypotension (systolic BP ≤ 110 mmHg for males or ≤ 100 mmHg for females)\n* Orthostatic hypotension (fall in systolic BP ≥ 20 mmHg and\u002For a fall in diastolic BP ≥ 10 mmHg within 10 minutes of assuming an upright position)\n* Daily fluctuation in systolic BP ≥ 20 mmHg and\u002For fluctuation in diastolic BP ≥ 10 mmHg\n* At least 14 years old\n\nExclusion Criteria:\n\n* Implanted brain\u002Fspine\u002Fnerve stimulators\n* Cochlear implants\n* Cardiac pacemaker\u002Fdefibrillator, or intracardiac lines\n* Open skin lesions on or near the electrode placement sites (neck, upper back)\n* Significant coronary artery or cardiac conduction disease\n* Recent history of myocardial infarction\n* Insufficient mental capacity to understand and independently provide consent\n* Pregnancy\n* Cancer\n* Deemed unsuitable by study physician","100 Years",{"count":405,"type":20},50,[23],"Current forms of pharmacologic and non-pharmacologic treatments for hypotension and orthostatic hypotension (OH) remain inadequate during acute inpatient rehabilitation (AIR) following a traumatic spinal cord injury (SCI). A critical need exists for the identification of safe, practical, and effective treatment options that stabilize blood pressure (BP) after traumatic SCI. Recent published evidence suggests that transcutaneous Spinal Cord Stimulation (TSCS) can be used to raise seated BP, and mitigate the falls in BP during orthostatic repositioning in individuals with chronic SCI. This site-specific project will focus on the use of TSCS to stabilizing seated BP and mitigate the fall in BP during orthostatic repositioning during AIR following traumatic SCI.",[409,141,27,410,411,412,413,414],"Acute Spinal Cord Injury","Traumatic Spinal Cord Injury","Spinal Cord Stimulation","SCI - Spinal Cord Injury","Blood Pressure","Blood Pressure Disorders","2024-04-01",{"date":417,"type":32},"2024-04-02",{"date":419,"type":32},"2022-01-01",{"date":421,"type":20},"2026-10-01",{"name":423,"class":424},"Jill M. Wecht, Ed.D.","FED"]